Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $125 to $128.
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $125 to $128.